Abstract

Apocynin is an inhibitor of NADPH oxidase present in inflammatory cells such as eosinophils and neutrophils. We investigated the effect of inhaled apocynin on ozone-induced bronchial hyperresponsiveness in vivo. Seven mild atopic asthmatics participated in a placebo-controlled, cross-over study with two exposures to O 3 at 2-week intervals. Apocynin (3 ml of 0.5 mg/ml) was inhaled 2 times before and 6 times after O 3 exposure at hourly intervals. At 36 h before and 16 h after O 3 exposure, methacholine inhalation challenge tests (Mch) were performed, and PC 20 and maximal % fall from baseline (MFEV 1) were calculated from dose-response curves. O 3-induced change in PC 20 (ΔPC 20) after placebo treatment was −1.94 ± 0.39 DD (mean ± SEM doubling dose Mch) ( p = .001) and apocynin was −0.6 ± 0.33 DD ( p = .17). The difference between apocynin and placebo treatment was 1.3 DD ± 0.42 ( p = .02). O 3-induced ΔMFEV 1 was 11.9 ± 1.5% ( p = .008) during placebo inhalation and 3.85 ± 1.8% during apocynin ( p = .47). Apocynin reduced the ΔMFEV 1 by 8.05% compared to placebo ( p = .025). We conclude that apocynin markedly reduced O 3-induced hyperreactivity for Mch as well as maximal airway narrowing. The results suggest that apocynin may have a role in preventing ozone-induced exacerbations of asthma.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call